December 3, 2024

$1,31B

$200M

–

–

$1.11B

Undisclosed

–

Keros Therapeutics granted Takeda exclusive, worldwide (excluding mainland China, Hong Kong, and Macau) rights to develop, manufacture, and commercialize Keros’ elritercept, a late-stage investigational activin inhibitor for the treatment of all indications.

Dev and Commercial License

Collaborative Development, No Shared Cost

• Takeda granted exclusive worldwide rights (excluding mainland China, Hong Kong, and Macau) to develop, manufacture, and commercialize Keros’ elritercept.
• Elritercept, an investigational activin inhibitor, received FDA Fast Track designation for treating very low, low, and intermediate-risk myelodysplastic syndromes (MDS).
• Two Phase II trials are ongoing: one for MDS patients and another for myelofibrosis (MF) patients.
• Phase III trial (RENEW) will evaluate elritercept in transfusion-dependent anemia in MDS patients and is set to start soon.
• Keros will receive $200M up front and up to $370M in development and commercial milestones.
• Keros is eligible for up to $740M in sales milestones and royalties ranging from low double-digits to high teens.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.